Chronic Kidney Disease-Mineral and Bone Disorders: Pathogenesis and Management

Calcif Tissue Int. 2021 Apr;108(4):410-422. doi: 10.1007/s00223-020-00777-1. Epub 2020 Nov 15.

Abstract

The key players of the chronic kidney disease-mineral and bone disorders (CKD-MBD) are calcium, phosphate, PTH, FGF23, and the vitamin D hormonal system. The progressive reduction of kidney function greatly modifies the tightly interrelated mechanisms that control these parameters. As a result, important changes occur in the bone and mineral hormonal axis, leading to changes in bone turnover with relevant consequences in clinical outcomes, such as decrease in bone mass with increased bone fragility and bone fractures and increased vascular and valvular calcification, also with great impact in the cardiovascular outcomes. So far, the knowledge of the mineral and bone disorders in CKD and the increased variety of efficacious therapies should lead to a better prevention and management of CKD-MBD.

Keywords: Bone disorders; Bone fractures; CKD-MBD; Osteoporosis; Renal osteodystrophy; Secondary hyperparathyroidism; Vascular calcification.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Bone Density
  • Calcium
  • Chronic Kidney Disease-Mineral and Bone Disorder* / therapy
  • Fibroblast Growth Factor-23
  • Humans
  • Phosphates
  • Renal Insufficiency, Chronic* / complications
  • Renal Insufficiency, Chronic* / therapy
  • Vitamin D

Substances

  • FGF23 protein, human
  • Phosphates
  • Vitamin D
  • Fibroblast Growth Factor-23
  • Calcium